Wang Chunbin, Xiong Bo, Huang Jing
Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Nutrients. 2016 Dec 30;9(1):18. doi: 10.3390/nu9010018.
Many new clinical trials about the effect of omega-3 polyunsaturated fatty acids (PUFAs) in heart failure (HF) patients have shown inconsistent results. Therefore, a meta-analysis of randomised controlled trials (RCTs) was performed to determine the benefits of omega-3 PUFAs in HF patients. Articles were obtained from PubMed, EMBASE, and the Cochrane Library. RCTs comparing omega-3 PUFAs with placebo for HF were included. Two reviewers independently extracted the data from the selected publications. The ² statistic was used to assess heterogeneity. The pooled mean difference and associated 95% confidence intervals were calculated, and a fixed or random-effects model was used for the meta-analysis. A total of nine RCTs involving 800 patients were eligible for inclusion. Compared with patients taking placebo, HF patients who received omega-3 PUFAs experienced decreased brain natriuretic peptide levels and serum norepinephrine levels. Although the left ventricular ejection fraction (LVEF) and clinical outcomes (Tei index, peak oxygen consumption) did not improve, subgroup analysis showed that the LVEF increased in dilated cardiomyopathy (DCM) patients. Overall, omega-3 PUFA supplements might be beneficial in HF patients, especially in DCM patients, but further studies are needed to confirm these benefits.
许多关于ω-3多不饱和脂肪酸（PUFAs）对心力衰竭（HF）患者影响的新临床试验结果并不一致。因此，进行了一项随机对照试验（RCT）的荟萃分析，以确定ω-3 PUFAs对HF患者的益处。文章来源于PubMed、EMBASE和Cochrane图书馆。纳入了比较ω-3 PUFAs与安慰剂治疗HF的RCT。两名 reviewers 独立从选定的出版物中提取数据。使用²统计量评估异质性。计算合并平均差和相关的95%置信区间，并使用固定或随机效应模型进行荟萃分析。共有9项涉及800名患者的RCT符合纳入标准。与服用安慰剂的患者相比，接受ω-3 PUFAs的HF患者脑钠肽水平和血清去甲肾上腺素水平降低。虽然左心室射血分数（LVEF）和临床结局（Tei指数、峰值耗氧量）没有改善，但亚组分析显示扩张型心肌病（DCM）患者的LVEF增加。总体而言，补充ω-3 PUFA可能对HF患者有益，尤其是对DCM患者，但需要进一步研究来证实这些益处。
